Intrinsic value of REGENXBIO Inc. - RGNX

Previous Close

$57.79

  Intrinsic Value

$3.50

stock screener

  Rating & Target

str. sell

-94%

Previous close

$57.79

 
Intrinsic value

$3.50

 
Up/down potential

-94%

 
Rating

str. sell

We calculate the intrinsic value of RGNX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  350
  541
  810
  1,175
  1,657
  2,278
  3,058
  4,016
  5,167
  6,527
  8,105
  9,909
  11,944
  14,211
  16,709
  19,437
  22,390
  25,563
  28,951
  32,550
  36,354
  40,359
  44,563
  48,963
  53,560
  58,352
  63,344
  68,537
  73,936
  79,548
Variable operating expenses, $m
  582
  900
  1,346
  1,952
  2,755
  3,787
  5,083
  6,674
  8,588
  10,848
  13,470
  16,469
  19,850
  23,618
  27,771
  32,304
  37,211
  42,485
  48,117
  54,097
  60,420
  67,077
  74,063
  81,377
  89,016
  96,981
  105,277
  113,908
  122,882
  132,209
Fixed operating expenses, $m
  73
  74
  76
  77
  79
  81
  83
  85
  86
  88
  90
  92
  94
  96
  98
  101
  103
  105
  107
  110
  112
  115
  117
  120
  122
  125
  128
  131
  133
  136
Total operating expenses, $m
  655
  974
  1,422
  2,029
  2,834
  3,868
  5,166
  6,759
  8,674
  10,936
  13,560
  16,561
  19,944
  23,714
  27,869
  32,405
  37,314
  42,590
  48,224
  54,207
  60,532
  67,192
  74,180
  81,497
  89,138
  97,106
  105,405
  114,039
  123,015
  132,345
Operating income, $m
  -305
  -433
  -612
  -855
  -1,176
  -1,589
  -2,107
  -2,743
  -3,507
  -4,409
  -5,456
  -6,652
  -8,001
  -9,504
  -11,160
  -12,968
  -14,925
  -17,028
  -19,273
  -21,658
  -24,178
  -26,832
  -29,618
  -32,533
  -35,579
  -38,754
  -42,061
  -45,502
  -49,079
  -52,797
EBITDA, $m
  -298
  -423
  -597
  -834
  -1,147
  -1,548
  -2,052
  -2,671
  -3,414
  -4,292
  -5,310
  -6,474
  -7,786
  -9,248
  -10,860
  -12,619
  -14,522
  -16,568
  -18,753
  -21,073
  -23,525
  -26,107
  -28,817
  -31,654
  -34,617
  -37,706
  -40,923
  -44,271
  -47,751
  -51,368
Interest expense (income), $m
  0
  0
  1
  3
  5
  9
  13
  18
  25
  33
  43
  55
  69
  84
  102
  121
  143
  167
  192
  219
  249
  280
  313
  347
  384
  422
  462
  503
  546
  591
  638
Earnings before tax, $m
  -305
  -434
  -615
  -861
  -1,185
  -1,602
  -2,125
  -2,768
  -3,540
  -4,452
  -5,511
  -6,720
  -8,085
  -9,605
  -11,281
  -13,111
  -15,091
  -17,220
  -19,492
  -21,906
  -24,458
  -27,145
  -29,965
  -32,917
  -36,001
  -39,216
  -42,564
  -46,048
  -49,670
  -53,435
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -305
  -434
  -615
  -861
  -1,185
  -1,602
  -2,125
  -2,768
  -3,540
  -4,452
  -5,511
  -6,720
  -8,085
  -9,605
  -11,281
  -13,111
  -15,091
  -17,220
  -19,492
  -21,906
  -24,458
  -27,145
  -29,965
  -32,917
  -36,001
  -39,216
  -42,564
  -46,048
  -49,670
  -53,435

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  392
  606
  907
  1,315
  1,856
  2,551
  3,425
  4,497
  5,787
  7,309
  9,076
  11,096
  13,375
  15,913
  18,711
  21,766
  25,072
  28,626
  32,420
  36,450
  40,709
  45,195
  49,902
  54,830
  59,977
  65,344
  70,933
  76,749
  82,795
  89,080
Adjusted assets (=assets-cash), $m
  392
  606
  907
  1,315
  1,856
  2,551
  3,425
  4,497
  5,787
  7,309
  9,076
  11,096
  13,375
  15,913
  18,711
  21,766
  25,072
  28,626
  32,420
  36,450
  40,709
  45,195
  49,902
  54,830
  59,977
  65,344
  70,933
  76,749
  82,795
  89,080
Revenue / Adjusted assets
  0.893
  0.893
  0.893
  0.894
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
  0.893
Average production assets, $m
  34
  53
  79
  114
  161
  221
  297
  390
  501
  633
  786
  961
  1,159
  1,378
  1,621
  1,885
  2,172
  2,480
  2,808
  3,157
  3,526
  3,915
  4,323
  4,749
  5,195
  5,660
  6,144
  6,648
  7,172
  7,716
Working capital, $m
  -8
  -12
  -19
  -27
  -38
  -52
  -70
  -92
  -119
  -150
  -186
  -228
  -275
  -327
  -384
  -447
  -515
  -588
  -666
  -749
  -836
  -928
  -1,025
  -1,126
  -1,232
  -1,342
  -1,457
  -1,576
  -1,701
  -1,830
Total debt, $m
  27
  58
  101
  159
  236
  336
  461
  614
  798
  1,016
  1,269
  1,558
  1,883
  2,246
  2,647
  3,083
  3,556
  4,064
  4,607
  5,183
  5,792
  6,434
  7,107
  7,812
  8,548
  9,315
  10,114
  10,946
  11,811
  12,709
Total liabilities, $m
  56
  87
  130
  188
  265
  365
  490
  643
  827
  1,045
  1,298
  1,587
  1,913
  2,276
  2,676
  3,112
  3,585
  4,093
  4,636
  5,212
  5,821
  6,463
  7,136
  7,841
  8,577
  9,344
  10,143
  10,975
  11,840
  12,738
Total equity, $m
  336
  520
  777
  1,127
  1,591
  2,187
  2,935
  3,854
  4,959
  6,264
  7,778
  9,510
  11,462
  13,638
  16,036
  18,653
  21,487
  24,532
  27,784
  31,237
  34,888
  38,732
  42,766
  46,989
  51,400
  56,000
  60,790
  65,774
  70,956
  76,341
Total liabilities and equity, $m
  392
  607
  907
  1,315
  1,856
  2,552
  3,425
  4,497
  5,786
  7,309
  9,076
  11,097
  13,375
  15,914
  18,712
  21,765
  25,072
  28,625
  32,420
  36,449
  40,709
  45,195
  49,902
  54,830
  59,977
  65,344
  70,933
  76,749
  82,796
  89,079
Debt-to-equity ratio
  0.080
  0.110
  0.130
  0.140
  0.150
  0.150
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
Adjusted equity ratio
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857
  0.857

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -305
  -434
  -615
  -861
  -1,185
  -1,602
  -2,125
  -2,768
  -3,540
  -4,452
  -5,511
  -6,720
  -8,085
  -9,605
  -11,281
  -13,111
  -15,091
  -17,220
  -19,492
  -21,906
  -24,458
  -27,145
  -29,965
  -32,917
  -36,001
  -39,216
  -42,564
  -46,048
  -49,670
  -53,435
Depreciation, amort., depletion, $m
  6
  10
  15
  21
  30
  41
  55
  72
  93
  117
  146
  178
  215
  255
  300
  349
  402
  459
  520
  585
  653
  725
  800
  880
  962
  1,048
  1,138
  1,231
  1,328
  1,429
Funds from operations, $m
  -299
  -424
  -600
  -839
  -1,155
  -1,561
  -2,071
  -2,696
  -3,448
  -4,335
  -5,365
  -6,542
  -7,870
  -9,350
  -10,981
  -12,761
  -14,689
  -16,760
  -18,972
  -21,322
  -23,805
  -26,420
  -29,165
  -32,038
  -35,038
  -38,168
  -41,426
  -44,817
  -48,342
  -52,006
Change in working capital, $m
  -3
  -4
  -6
  -8
  -11
  -14
  -18
  -22
  -26
  -31
  -36
  -41
  -47
  -52
  -57
  -63
  -68
  -73
  -78
  -83
  -87
  -92
  -97
  -101
  -106
  -110
  -115
  -119
  -124
  -129
Cash from operations, $m
  -296
  -420
  -594
  -831
  -1,144
  -1,547
  -2,053
  -2,674
  -3,421
  -4,304
  -5,329
  -6,501
  -7,824
  -9,298
  -10,924
  -12,699
  -14,621
  -16,687
  -18,894
  -21,239
  -23,718
  -26,328
  -29,068
  -31,936
  -34,933
  -38,057
  -41,312
  -44,697
  -48,218
  -51,877
Maintenance CAPEX, $m
  -4
  -6
  -10
  -15
  -21
  -30
  -41
  -55
  -72
  -93
  -117
  -146
  -178
  -215
  -255
  -300
  -349
  -402
  -459
  -520
  -585
  -653
  -725
  -800
  -880
  -962
  -1,048
  -1,138
  -1,231
  -1,328
New CAPEX, $m
  -13
  -19
  -26
  -35
  -47
  -60
  -76
  -93
  -112
  -132
  -153
  -175
  -197
  -220
  -242
  -265
  -286
  -308
  -329
  -349
  -369
  -389
  -408
  -427
  -446
  -465
  -484
  -504
  -524
  -544
Cash from investing activities, $m
  -17
  -25
  -36
  -50
  -68
  -90
  -117
  -148
  -184
  -225
  -270
  -321
  -375
  -435
  -497
  -565
  -635
  -710
  -788
  -869
  -954
  -1,042
  -1,133
  -1,227
  -1,326
  -1,427
  -1,532
  -1,642
  -1,755
  -1,872
Free cash flow, $m
  -312
  -445
  -630
  -881
  -1,212
  -1,637
  -2,169
  -2,822
  -3,605
  -4,528
  -5,599
  -6,822
  -8,199
  -9,732
  -11,421
  -13,263
  -15,257
  -17,397
  -19,682
  -22,108
  -24,671
  -27,369
  -30,201
  -33,164
  -36,258
  -39,484
  -42,844
  -46,339
  -49,973
  -53,750
Issuance/(repayment) of debt, $m
  21
  31
  43
  58
  77
  99
  125
  153
  184
  218
  253
  289
  326
  363
  400
  437
  473
  508
  543
  576
  609
  641
  673
  705
  736
  767
  799
  832
  865
  899
Issuance/(repurchase) of shares, $m
  431
  617
  872
  1,211
  1,648
  2,198
  2,874
  3,687
  4,645
  5,757
  7,025
  8,452
  10,038
  11,781
  13,679
  15,728
  17,925
  20,265
  22,744
  25,360
  28,109
  30,989
  34,000
  37,140
  40,412
  43,815
  47,354
  51,032
  54,852
  58,821
Cash from financing (excl. dividends), $m  
  452
  648
  915
  1,269
  1,725
  2,297
  2,999
  3,840
  4,829
  5,975
  7,278
  8,741
  10,364
  12,144
  14,079
  16,165
  18,398
  20,773
  23,287
  25,936
  28,718
  31,630
  34,673
  37,845
  41,148
  44,582
  48,153
  51,864
  55,717
  59,720
Total cash flow (excl. dividends), $m
  140
  203
  285
  388
  513
  661
  830
  1,019
  1,225
  1,446
  1,679
  1,919
  2,164
  2,412
  2,658
  2,902
  3,141
  3,376
  3,605
  3,828
  4,047
  4,261
  4,472
  4,681
  4,889
  5,098
  5,310
  5,524
  5,744
  5,970
Retained Cash Flow (-), $m
  -431
  -617
  -872
  -1,211
  -1,648
  -2,198
  -2,874
  -3,687
  -4,645
  -5,757
  -7,025
  -8,452
  -10,038
  -11,781
  -13,679
  -15,728
  -17,925
  -20,265
  -22,744
  -25,360
  -28,109
  -30,989
  -34,000
  -37,140
  -40,412
  -43,815
  -47,354
  -51,032
  -54,852
  -58,821
Prev. year cash balance distribution, $m
  299
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  8
  -414
  -587
  -823
  -1,135
  -1,537
  -2,044
  -2,668
  -3,420
  -4,311
  -5,346
  -6,533
  -7,873
  -9,369
  -11,021
  -12,827
  -14,784
  -16,889
  -19,140
  -21,532
  -24,062
  -26,728
  -29,528
  -32,459
  -35,522
  -38,717
  -42,045
  -45,507
  -49,108
  -52,851
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  7
  -379
  -511
  -677
  -880
  -1,116
  -1,381
  -1,668
  -1,965
  -2,260
  -2,539
  -2,788
  -2,994
  -3,145
  -3,236
  -3,260
  -3,217
  -3,110
  -2,947
  -2,736
  -2,489
  -2,218
  -1,935
  -1,653
  -1,382
  -1,130
  -902
  -704
  -536
  -398
Current shareholders' claim on cash, %
  66.8
  46.2
  32.9
  23.9
  17.6
  13.2
  10.0
  7.7
  5.9
  4.6
  3.6
  2.9
  2.3
  1.8
  1.5
  1.2
  1.0
  0.8
  0.6
  0.5
  0.4
  0.4
  0.3
  0.2
  0.2
  0.2
  0.1
  0.1
  0.1
  0.1

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

FINANCIAL RATIOS  of  REGENXBIO Inc. (RGNX)

Valuation Ratios
P/E Ratio -24.3
Price to Sales 306.1
Price to Book 9.4
Price to Tangible Book
Price to Cash Flow -31.2
Price to Free Cash Flow -26.8
Growth Rates
Sales Growth Rate -37.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 700%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -32%
Ret/ On Assets - 3 Yr. Avg. -61.7%
Return On Total Capital -33.2%
Ret/ On T. Cap. - 3 Yr. Avg. 26.5%
Return On Equity -33.2%
Return On Equity - 3 Yr. Avg. 15.3%
Asset Turnover 0
Profitability Ratios
Gross Margin 80%
Gross Margin - 3 Yr. Avg. 79.4%
EBITDA Margin -1240%
EBITDA Margin - 3 Yr. Avg. -531.4%
Operating Margin -1300%
Oper. Margin - 3 Yr. Avg. -551.4%
Pre-Tax Margin -1260%
Pre-Tax Margin - 3 Yr. Avg. -538.1%
Net Profit Margin -1260%
Net Profit Margin - 3 Yr. Avg. -533.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

RGNX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RGNX stock intrinsic value calculation we used $219 million for the last fiscal year's total revenue generated by REGENXBIO Inc.. The default revenue input number comes from 0001 income statement of REGENXBIO Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RGNX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RGNX is calculated based on our internal credit rating of REGENXBIO Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of REGENXBIO Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RGNX stock the variable cost ratio is equal to 166.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $71 million in the base year in the intrinsic value calculation for RGNX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for REGENXBIO Inc..

Corporate tax rate of 27% is the nominal tax rate for REGENXBIO Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RGNX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RGNX are equal to 9.7%.

Life of production assets of 5.4 years is the average useful life of capital assets used in REGENXBIO Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RGNX is equal to -2.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $508.848 million for REGENXBIO Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 36.335 million for REGENXBIO Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of REGENXBIO Inc. at the current share price and the inputted number of shares is $2.1 billion.

RELATED COMPANIES Price Int.Val. Rating
VYGR Voyager Therap 17.93 0.32  str.sell
SGMO Sangamo Therap 8.89 2.23  str.sell
ONCE Spark Therapeu 113.00 3.26  str.sell
ABEO Abeona Therape 7.52 0.70  str.sell
AGTC Applied Geneti 4.17 6.63  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.